NCT06507683 Evaluate the Efficacy and Safety of Radiotherapy Combined With Ripretinib in the Treatment of Unresectable Advanced GIST
| NCT ID | NCT06507683 |
| Status | Recruiting |
| Phase | — |
| Sponsor | First Affiliated Hospital of Chongqing Medical University |
| Condition | Gastrointestinal Stromal Tumors |
| Study Type | INTERVENTIONAL |
| Enrollment | 32 participants |
| Start Date | 2024-05-28 |
| Primary Completion | 2027-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 32 participants in total. It began in 2024-05-28 with a primary completion date of 2027-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this prospective study is to learn whether there is a synergistic effect when radiotherapy is combined with ripretinib in the treatment of patients with unresectable advanced GIST. It will also learn about the safety of this regimen.The main questions it aim to answer is: Dose radiotherapy combined with ripretinib prolong the time to disease progression for patients with advanced GIST?
Eligibility Criteria
Inclusion Criteria: * Voluntary participation and signed informed consent; * age: 18 to 75 years, Male or female * Patients with histologically confirmed GIST and Imaging evaluated as unresectable recurrent and metastatic disease or locally advanced. * ECOG Performance Score: 0-2 * Subjects who have progressed or documented intolerance after previous first-line, second-line, and third-line treatments. * At least one measurable lesion in the abdominal or pelvic cavity that has progressed after frontline treatment * Adequate organ function and bone marrow reserve Exclusion Criteria: * estimated life-expectancy less than 3 months. * Patients who have received previous radiotherapy to the proposed radiotherapy site, or the tumor has significant mobility, poor tolerance of radiotherapy in adjacent organs, and who are considered unsuitable for radiotherapy after MDT discussion * Any other clinically significant comorbidities, which in the judgment of the investigator, could compromise compliance with the protocol, interfere with interpretation of the study results, or predispose the patient to safety risks. * If female, the patient is pregnant or lactating, or plans to become pregnant during the study treatment period
Contact & Investigator
Jun Zhang
PRINCIPAL INVESTIGATOR
First Affiliated Hospital of Chongqing Medical University
Frequently Asked Questions
Who can join the NCT06507683 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Gastrointestinal Stromal Tumors. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06507683 currently recruiting?
Yes, NCT06507683 is actively recruiting participants. Contact the research team at zjun2323@sina.cn for enrollment information.
Where is the NCT06507683 trial being conducted?
This trial is being conducted at Chongqing, China.
Who is sponsoring the NCT06507683 clinical trial?
NCT06507683 is sponsored by First Affiliated Hospital of Chongqing Medical University. The principal investigator is Jun Zhang at First Affiliated Hospital of Chongqing Medical University. The trial plans to enroll 32 participants.